NKTR Nektar Therapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: NKTR

Price (delayed)

$74.02

Market cap

$2.53B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.51

Enterprise value

$2.57B

?
Relative Growth: Rel. Growth: 16
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 31

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), ...

Highlights
Nektar Therapeutics's equity has surged by 57% QoQ
Nektar Therapeutics's EPS has increased by 25% YoY and by 21% QoQ
The net income has declined by 29% year-on-year
The revenue has contracted by 27% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nektar.com
Peers: PFE MRK AMGN BAX

Key stats

What are the main financial stats of NKTR

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
-0.68%
1 week
1.37%
1 month
7.79%
1 year
164.36%
YTD
75.07%
QTD
6.03%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$54.59M
Gross profit
$54.59M
Operating income
-$140.73M
Net income
-$157.13M
Gross margin
100%
Net margin
-287.8%
The operating margin has plunged by 92% YoY and by 7% from the previous quarter
The net margin has shrunk by 76% YoY
The operating income is down by 40% year-on-year and by 4.5% since the previous quarter
The net income has declined by 29% year-on-year

Price vs fundamentals

How does NKTR's price correlate with its fundamentals

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
2.77
P/S
44.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.02
Nektar Therapeutics's EPS has increased by 25% YoY and by 21% QoQ
The P/B is 61% below the last 4 quarters average of 7.1 and 21% below the 5-year quarterly average of 3.5
Nektar Therapeutics's equity has surged by 57% QoQ
The stock's P/S is 72% more than its last 4 quarters average of 26.1
The revenue has contracted by 27% YoY

Efficiency

How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's ROE has soared by 92% YoY and by 56% from the previous quarter
Nektar Therapeutics's return on sales has shrunk by 80% YoY
NKTR's ROA is up by 43% YoY and by 37% from the previous quarter
The return on invested capital has grown by 40% since the previous quarter and by 39% year-on-year

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets has increased by 43% from the previous quarter
The total liabilities has contracted by 17% YoY but it has grown by 2.6% from the previous quarter
The debt is 91% lower than the equity
The debt to equity has soared by 102% YoY but it fell by 36% QoQ
Nektar Therapeutics's equity has surged by 57% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.